Richmond Pharmacology Appoints John Hotti as Chief Technology Officer

Richmond Pharmacology is pleased to announce the appointment of John Hotti as Chief Technology Officer (CTO), strengthening the company’s leadership in technology-enabled clinical research.

John brings over 35 years of global technology leadership across Software as a Service (SaaS), financial services, healthcare, and enterprise systems. He has led large-scale digital transformations, stabilised mission-critical platforms, and delivered secure, scalable technology in highly regulated environments. His experience spans hands-on engineering through to board-level advisory, including supporting major investment decisions and post-acquisition integrations.

In his role at Richmond, John will lead the development of a progressive technology and data strategy to enhance trial delivery, strengthen cybersecurity and compliance, and enable the responsible adoption of AI across clinical operations. This includes advancing platforms that improve data quality, accelerate study timelines, and support more efficient, reliable outcomes for sponsors and patients.

John Hotti commented:
"I am delighted to be joining Richmond Pharmacology and working with its exceptional people. My focus will be on building on the strong foundations already in place, advancing our technology and cybersecurity capabilities, and ensuring the responsible use of emerging technologies such as generative AI to deliver secure, scalable, resilient platforms that enhance operational performance across the business and support the company’s long-term goals."

Chief Executive Officer, Dr Jorg Taubel, added:
"We are very pleased to welcome John to Richmond. His experience in delivering secure, scalable technology in regulated environments will be instrumental as we continue to enhance our data capabilities and adopt AI responsibly, supporting high-quality, efficient clinical trials for our partners."

With deep expertise in AI strategy, cloud architecture, and regulated systems, John will play a key role in strengthening Richmond’s ability to deliver faster, more data-driven clinical research—supporting the development of innovative therapies for patients.

ENDS

Media Contact:
Linda Rose

Linda@denhams.digital
Denham’s Digital

About Richmond Pharmacology:

Founded in 2001, Richmond Pharmacology is a leading Contract Research Organisation (CRO) with a heritage in first-in-human and adaptive clinical trials. It has conducted around 20% of all UK Phase I studies and has recognised expertise in advanced modalities, including in-vivo gene editing. Richmond dosed the first patient in the world with a systemically delivered, in‑vivo CRISPR–Cas9 therapeutic marking a global milestone in genomic medicine.

Today, Richmond supports global pharmaceutical, biotech, and genetic engineering partners, including a wide range of global pharmaceutical and biotechnology partners. In 2020, it established the Richmond Research Institute to expand understanding of under-researched diseases—supporting its mission to deliver faster answers for patients and partners.